Aim: To evaluate the therapeutic effects of switching from one acetylcholinesterase inhibitor (ChEI), donepezil, galantamine or rivastigmine, to another in Alzheimer's disease patients.
Introduction
Alzheimer's disease (AD) is a main cause of dementia, and mild to moderate cases are usually treated with acetylcholinesterase inhibitors (ChEI). 1 In Japan, three ChEI (donepezil, galantamine and rivastigmine) are currently available; the efficacy of these in Japanese AD patients has been reported in previous studies. [2] [3] [4] [5] However, AD patients sometimes discontinue ChEI therapy or have to switch to another ChEI because of side-effects, a rapid decline in cognitive function or hospitalization unrelated to AD. 6 Previous reports have shown that switching from one ChEI to another is beneficial in improving cognitive and affective functions, and activities of daily living (ADL) in AD patients. [7] [8] [9] [10] However, most previous reports have focused on the switch from donepezil to galantamine (D → G) or to rivastigmine (D → R), as donepezil was the first ChEI used for the treatment of AD. [6] [7] [8] [9] [10] [11] [12] Only one report has investigated the effect of switching from rivastigmine to galantamine (R → G). 9 Thus the effect of switching between ChEI has not been fully investigated, particularly from galantamine to donepezil (G → D) or to rivastigmine (G → R), and from rivastigmine to donepezil (R → D).
In the present study, we evaluated the therapeutic effects of switching from one ChEI to another (six combinations of drug switch between three ChEI: galantamine, donepezil and rivastigmine) on three major aspects of dementia: cognitive and affective functioning, and ADL.
Methods
The electronic database of Okayama University Hospital, Okayama, Japan, was used for the present retrospective clinical cohort study. We enrolled 171 patients with AD who had been treated with one ChEI and then switched to another. AD was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition or the International Classification of Diseases, Tenth Revision. 13 The 171 patients were divided into three main groups based on the drug treatment before the switch: donepezil (group D), galantamine (group G) and rivastigmine (group R). Each main group was further divided into two subgroups based on the drug switched to: 101 patients switched from donepezil to galantamine or rivastigmine (90 D → G, 11 D → R), 49 patients switched from galantamine to donepezil or rivastigmine (17 G → D, 32 G → R) and 21 patients switched from rivastigmine to donepezil or galantamine (9 R → D, 12 R → G).
All 171 patients were evaluated by six different tests for cognitive, affective and ADL assessments. The Mini-Mental State Examination (MMSE) 14 and Hasegawa Dementia Rating Scale-Revised (HDS-R) 15 were used for cognitive assessments. The Geriatric Depression Scale (GDS), 16 Apathy Scale (AS) 17 and Abe's Behavioral and Psychological Symptoms of Dementia (BPSD) score (ABS) 18 were used for affective assessments (depression, apathy and BPSD, respectively). The Alzheimer's Disease Co-operative Study -Activities of Daily Living Inventory was used for assessing ADL. 19 Medical records were reviewed to evaluate the six different tests at 6 months (M) before the drug switch (pre-switch assessment) to determine the severity of deterioration before switching drugs, at the time of drug switch (baseline assessment), and at 3 M and 6 M after switching drugs (post-switch assessments) to assess the efficacy of the new drug against further deterioration. The changes between the results of the pre-switch and baseline, and between the baseline and 3 M or 6 M after drug switch were compared for each score. Clinical demographic data such as age, sex and educational history, were also analyzed.
Comparisons between baseline characteristics (sex, age and years of education) and the baseline clinical scores of the each of the six subgroups were carried out using the Mann-Whitney U-test for continuous variables, and Pearson's χ 2 -test for comparing proportions. Comparisons between the mean drug doses in each of the different groups and subgroups were carried out using the Mann-Whitney U-test. Changes in clinical assessment scores between baseline and 6 M pre-switch, and 3 M and 6 M post-switch were analyzed using the Wilcoxon signed-rank test. All statistical analyses were carried out using SPSS-J for Windows version 21.0 (IBM Corporation, Armonk, NY, USA). A P-value of <0.05 was considered significant.
All of the participants gave written informed consent. This study was approved by the ethics committee of Okayama University (approval # 694). This study obtained exempted approval from the institutional review board based on the Okayama University guidelines because of the use of an anonymized and untraceable dataset.
Results
The baseline characteristics of each subgroup at the time of switching are shown in Table 1 . No significant differences were found between the subgroups in all three main groups (groups D, G and R; switching from donepezil, galantamine and rivastigmine, respectively) in the six clinical scores measured (MMSE, HDS-R, GDS, AS, ABS and ADL), as well as sex, age and years of education (Table 1) .
Immediately before switching, the ChEI doses were 5.8 AE 2.7 mg/day for group D, 13.7 AE 5.4 mg/day for group G and 9.7 AE 4.9 mg/day for group R (the containing dose of transdermal rivastigmine patch). The pre-switch dose of donepezil in the subgroup that switched to galantamine (D → G) was slightly higher (5.8 AE 2.7 mg/day) than the subgroup that switched to rivastigmine (D → R, 5.3 AE 3.5 mg/day; *P = 0.020; Fig. 1 , left upper panel). There were no significant differences in the doses of galantamine or rivastigmine in groups G and R (Fig. 1 , middle and right upper panels).
At 6 M post-switch, the mean doses of ChEI were 4.8 AE 3.2 mg/day for donepezil, 9.3 AE 3.1 mg/day for galantamine and 5.0 AE 2.4 mg/day for rivastigmine, which were lower than those before the switch ( † † † P = 0.000 for all three ChEI). However, there were no significant differences between subgroups in the mean doses of donepezil, galantamine or rivastigmine at 6 M post-switch (Fig. 1, lower panels) .
The effects of all drug switches as assessed by the six clinical scores (MMSE, HDS-R, GDS, AS, ABS and ADL) are shown in Figure 2 . Although the cognitive scores (MMSE and HDS-R) had significantly declined pre-switch ( ### P = 0.000), switching from donepezil to galantamine (D → G) stopped any further decline at 3 M and 6 M (Fig. 2a, b , filled squares), but not significantly. The switch to rivastigmine (D→ R) also showed similar amelioration of the deterioration in cognitive scores (Fig. 2a,b, filled triangles) . In terms of affective functions, the switch from donepezil to rivastigmine (D → R) showed a significant worsening of AS at 3 M post-switch ( Fig. 2d ; *P = 0.046). Conversely, ADL scores continuously declined when switching from donepezil to galantamine (D → G) at 3 M and 6 M (Fig. 2f : filled squares; *P = 0.020 and 0.042, respectively), but not when switching from donepezil to rivastigmine (D → R, Fig. 2f,  filled triangles) .
In group G, cognitive scores (MMSE and HDS-R) significantly declined pre-switch in subgroup G → D (Fig. 2g,h; in subgroup G → R ( Fig. 2g; ## P = 0.003). This was ameliorated at 3 M and 6 M in subgroup G → D. Although changing from galantamine to rivastigmine (G → R) transiently improved MMSE scores at 3 M (Fig. 2g , filled triangles; *P = 0.023), a subsequent deterioration of MMSE and HDS-R scores was found at 6 M (Fig. 2g,h , filled triangles; *P = 0.021 and **P = 0.010, respectively). Switching from galantamine to donepezil (G → D) or rivastigmine (G → R) did not affect the affective functions of GDS or AS at both follow-up points (Fig. 2i,j) . ABS significantly improved in both the galantamine to donepezil (G → D; Fig. 2k, filled circles) and to rivastigmine (G → R; Fig. 2k , filled triangles) subgroups at 3 M post-switch (*P = 0.042 and 0.035, respectively), but there was no further improvement at 6 M (Fig. 2k) . ADL scores significantly declined during pre-switch galantamine use, but was ameliorated at 3 M and 6 M after switching to rivastigmine (G → R; Fig. 2l , open square; # P = 0.031).
In group R, ABS scores significantly improved before the switch to galantamine (R → G; Fig. 2q , open triangles; # P = 0.048), stabilizing at 3 M and 6 M post-switch (Fig. 2q , (Fig. 2m-p,r) .
Discussion
In the present study, we first investigated the doses of ChEI before and after switching to another drug. The dose of galantamine was relatively low (13.7 AE 5.4 mg/day) before switching, but the low dose of galantamine is also effective for improving cognitive and affective functions for Japanese patients. 5, 20 The doses of all three ChEI were significantly lower at 6 M post-switch compared with pre-switch, suggesting that the relatively lower doses of ChEI were effective after switching. Despite the lower doses, switching ChEI resulted in well-preserved cognitive functions in subgroups D → G and G → D, and improved BPSD in subgroups G → D and G→ R, but worsened apathy, BPSD, and ADL in subgroups D → R, R → D and D → G, respectively, at 3 M or 6 M. Three ChEI have their own characteristics; Donepezil has a longer half-life compared with others. 8 Galantamine also allosterically modulates neuronal nicotinic receptors.
9,10 Rivastigmine also inhibits butyrylcholinesterase. 3 Therefore, switching of ChEI could show a different effect (improvement or worsening), despite the lower doses in the present study.
Switching from donepezil to galantamine (D → G) stopped any further decline in cognitive functioning from pre-switch levels. A previous report showed that switching from donepezil to galantamine (D → G) significantly improved MMSE scores at 3 M post-switch. 10 Switching from donepezil to rivastigmine (D → R) also ameliorated cognitive deterioration. This supports the findings of previous studies that showed improvements in MMSE scores in 48.9-55.0% of patients after switching from donepezil to rivastigmine (D → R). 7, 8, 11 However, one report failed to show any such benefit. 12 There have been no previous reports of switching from galantamine to another ChEI. In the present study, switching from galantamine to donepezil (G → D) stopped the decline that was occurring pre-switch, but switching from galantamine to rivastigmine (G → R) resulted in deterioration of MMSE and HDS-R scores at 6 M. Although a previous report showed that switching from rivastigmine to galantamine (R → G) significantly improved MMSE scores, switching from rivastigmine to donepezil (R → D) or to galantamine (R → G) did not affect cognitive functioning in the present study. 9 In terms of affective functions, switching from donepezil to rivastigmine (D → R) resulted in worsened apathy at 3 M post-switch, which has not been reported previously. 7, 8, 11, 12 Of interest was that all six combinations of switch had no effect on depression. This is contrary to a previous report that showed improvements in depression and apathy when switching from donepezil or rivastigmine to galantamine (D → G or R → G). 9 The present study and previous studies showed no effect on BPSD in switching from donepezil to galantamine or rivastigmine (D → G or D → R). 10, 12 However, in the present study, switching from galantamine to donepezil (G → D) or to rivastigmine (G → R), or from rivastigmine to galantamine (R → G), improved BPSD. Switching from rivastigmine to donepezil (R → D) worsened BPSD, which has not been reported previously.
Switching from donepezil to galantamine (D → G) worsened ADL measures in the present study, which is in contrast with the findings of a previous report. 10 This discrepancy might be related to the dose of galantamine after the switch; that is, a higher dose of galantamine in the previous study (16 or 24 mg/day) compared with the present study (9.4 AE 3.1 mg/day). 10 Although switching from donepezil to rivastigmine (D → R) did not affect ADL in the present study, a previous report showed a benefit of this drug switch in 57.0% of patients. 7 However, another report showed an adverse result. 12 Conversely, in the present study the switching from galantamine to rivastigmine (G → R) ameliorated the decline of ADL, but switching from galantamine to donepezil (G → D) did not, which has not been reported previously.
In conclusion, the present study comprehensively examined six combinations of drug switch between three ChEI until 6 M post-switch, and found benefits of the drug switch from galantamine to donepezil (G → D), but not to rivastigmine (G → R), in cognitive functions, and of the switch from rivastigmine to galantamine (R → G), but not to donepezil (R → D), for affective functions. The switch from donepezil to galantamine (D → G), but not to rivastigmine (D → R), was beneficial for affective functioning, but had an adverse effect on ADL. It is possible that if the post-switch doses were higher in the present study, more significant benefits for cognitive and affective functions and ADL might have been seen.
